<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01598207</url>
  </required_header>
  <id_info>
    <org_study_id>201003768</org_study_id>
    <nct_id>NCT01598207</nct_id>
  </id_info>
  <brief_title>The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yehudith Assouline-Dayan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <brief_summary>
    <textblock>
      Background: Noncardiac chest pain (NCCP) affects 200,000 new cases annually in USA. It is
      associated with poor quality of life and high health care expenditure of 8 Billion Dollars a
      year.

      Gastroesophageal Reflux Disease(GERD), esophageal motility disorders, and psychological
      issues may cause NCCP.

      The mechanism(s) for pain continue to be explored and include central and peripheral
      hypersensitivity, and mechanophysical abnormalities. Treatment of NCCP has focused on
      relieving visceral hypersensitivity through pain modulators, such as tricyclics, trazodone,
      or adenosine receptor antagonist, theophylline. Typically, only 40-50 % respond and clearly
      there is a large unmet therapeutic need.

      Cannabis is felt to be beneficial for vomiting, diarrhea and intestinal pain. The main
      component of Cannabis acts through specific receptors, that are located primarily on central
      and peripheral neurons (including the enteric nervous system) and myenteric plexus where they
      modulate neurotransmitter release. Activation of these receptors reduces excitatory enteric
      transmission and may improve esophageal hyperreactivity and hypersensitivity, the hallmarks
      of NCCP.

      STUDY PROTOCOL: The investigators will randomize 40 subjects with non-cardiac, non-reflux
      chest pain to receive dronabinol (5 mg Bid), or placebo for 4 weeks. Chest pain symptoms and
      esophageal sensorimotor properties will be assessed at baseline and at 4 weeks using symptom
      diary and impedance planimetry. The primary outcome measure will be the frequency of chest
      pain episodes. Secondary outcome measures include improvement in esophageal sensory
      thresholds, reduced reactive contractions, frequency, amplitude, area under the curve, and
      global improvement of symptoms.

      HYPOTHESIS: Cannabinoids decrease esophageal hypersensitivity and ameliorate chest pain in
      NCCP patients, when compared to placebo.

      AIM: To perform a randomized double blind study to investigate the effects of Dronabinol, a
      CB1 and CB2 agonist, in the treatment of patients with NCCP and examine its mechanism of
      action.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Chest Pain Episodes</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>Number of people still experiencing the same amount of chest pain during treatment than previously without</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Chest Pain in Treatment Group vs Baseline</measure>
    <time_frame>1 month</time_frame>
    <description>Total (intensity (0(none) - 3(severe) + duration (0(none) - 3(longer than 30 mins)) at end of 1 month treatment; higher represents worse outcome; the total score ranges from 0 to 6 and is the sum of the intensity and duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Chest Pain Episodes</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>Intensity (0(none) - 3(severe)) at baseline vs 1 month for chest pain episodes; higher represents worse outcome; multiple chest pain totals are averaged</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory Thresholds for First Sensation</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>This is determined by the Esophageal Balloon Distension Test; range 0-65 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Chest Pain Episodes</measure>
    <time_frame>Baseline vs 1 month</time_frame>
    <description>0 - is none and 3 is longer than 30 mins; higher values is worst outcome; chest pain totals are averaged</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory Thresholds for Discomfort</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>When participants felt pain at earliest pressure; range 0-65 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory Thresholds for Pain</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>When highest amount of pain was felt; range is 0-65 mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Chest Pain</condition>
  <arm_group>
    <arm_group_label>Marinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marinol</intervention_name>
    <description>5mg BID, orally for 1 month</description>
    <arm_group_label>Marinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5mg BID, orally for 1 month</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female

          -  Ages 18-75 years

          -  Non-GERD related Non cardiac chest pain (Evaluated previously with an EGD, Esophageal
             manometry, and 24 Hour ambulatory pH study)

          -  At least one episode of chest pain a week in the past month

          -  Previous negative cardiac evaluation (EKG ± Non invasive stress test ± Coronary
             angiogram)

        Exclusion Criteria:

          -  Subjects requiring narcotics or other pain medications

          -  Subjects with known esophagitis, Barrett's esophagus or peptic stricture on endoscopy

          -  Subjects with previous upper gastrointestinal surgery

          -  Pregnancy

          -  Subjects with Diabetes, neuromuscular disorders, or other severe co-morbidities
             (Cardiovascular, respiratory, renal, hepatic, hematologic, endocrine, neurologic, and
             psychiatric)

          -  Subjects with upper airway symptoms (such as hoarseness, wheezing or laryngospasm)

          -  Medications such as baclofen, H2 blockers, PPI, sucralfate and prokinetics.

          -  Known history of substance abuse

          -  Nursing mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <results_first_submitted>March 21, 2016</results_first_submitted>
  <results_first_submitted_qc>April 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 28, 2017</results_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Yehudith Assouline-Dayan</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chest Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Marinol</title>
          <description>Marinol: 5mg BID, orally for 1 month</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: 5mg BID, orally for 1 month</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Marinol</title>
          <description>Marinol: 5mg BID, orally for 1 month</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: 5mg BID, orally for 1 month</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Chest Pain Episodes</title>
        <description>Number of people still experiencing the same amount of chest pain during treatment than previously without</description>
        <time_frame>Baseline and 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Marinol</title>
            <description>Marinol: 5mg BID, orally for 1 month</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 5mg BID, orally for 1 month</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Chest Pain Episodes</title>
          <description>Number of people still experiencing the same amount of chest pain during treatment than previously without</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Chest Pain in Treatment Group vs Baseline</title>
        <description>Total (intensity (0(none) - 3(severe) + duration (0(none) - 3(longer than 30 mins)) at end of 1 month treatment; higher represents worse outcome; the total score ranges from 0 to 6 and is the sum of the intensity and duration</description>
        <time_frame>1 month</time_frame>
        <population>1 participant in placebo did not have this information completed</population>
        <group_list>
          <group group_id="O1">
            <title>Marinol</title>
            <description>Marinol: 5mg BID, orally for 1 month</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 5mg BID, orally for 1 month</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Chest Pain in Treatment Group vs Baseline</title>
          <description>Total (intensity (0(none) - 3(severe) + duration (0(none) - 3(longer than 30 mins)) at end of 1 month treatment; higher represents worse outcome; the total score ranges from 0 to 6 and is the sum of the intensity and duration</description>
          <population>1 participant in placebo did not have this information completed</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="2.58"/>
                    <measurement group_id="O2" value="1.8" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of Chest Pain Episodes</title>
        <description>Intensity (0(none) - 3(severe)) at baseline vs 1 month for chest pain episodes; higher represents worse outcome; multiple chest pain totals are averaged</description>
        <time_frame>Baseline and 1 month</time_frame>
        <population>1 participant in placebo did not have this information completed</population>
        <group_list>
          <group group_id="O1">
            <title>Marinol</title>
            <description>Marinol: 5mg BID, orally for 1 month</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 5mg BID, orally for 1 month</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Chest Pain Episodes</title>
          <description>Intensity (0(none) - 3(severe)) at baseline vs 1 month for chest pain episodes; higher represents worse outcome; multiple chest pain totals are averaged</description>
          <population>1 participant in placebo did not have this information completed</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.82"/>
                    <measurement group_id="O2" value="0.6" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="1.03"/>
                    <measurement group_id="O2" value="0.8" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensory Thresholds for First Sensation</title>
        <description>This is determined by the Esophageal Balloon Distension Test; range 0-65 mmHg</description>
        <time_frame>Baseline and 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Marinol</title>
            <description>Marinol: 5mg BID, orally for 1 month</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 5mg BID, orally for 1 month</description>
          </group>
        </group_list>
        <measure>
          <title>Sensory Thresholds for First Sensation</title>
          <description>This is determined by the Esophageal Balloon Distension Test; range 0-65 mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread=".125"/>
                    <measurement group_id="O2" value="2.7" spread=".103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Chest Pain Episodes</title>
        <description>0 - is none and 3 is longer than 30 mins; higher values is worst outcome; chest pain totals are averaged</description>
        <time_frame>Baseline vs 1 month</time_frame>
        <population>1 participant in placebo did not have this information completed</population>
        <group_list>
          <group group_id="O1">
            <title>Marinol</title>
            <description>Marinol: 5mg BID, orally for 1 month</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 5mg BID, orally for 1 month</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Chest Pain Episodes</title>
          <description>0 - is none and 3 is longer than 30 mins; higher values is worst outcome; chest pain totals are averaged</description>
          <population>1 participant in placebo did not have this information completed</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="1.17"/>
                    <measurement group_id="O2" value="1" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.64"/>
                    <measurement group_id="O2" value="1" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensory Thresholds for Discomfort</title>
        <description>When participants felt pain at earliest pressure; range 0-65 mmHg</description>
        <time_frame>Baseline and 1 month</time_frame>
        <population>1 participant in marinol and 1 participant in placebo did not have this information completed</population>
        <group_list>
          <group group_id="O1">
            <title>Marinol</title>
            <description>Marinol: 5mg BID, orally for 1 month</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 5mg BID, orally for 1 month</description>
          </group>
        </group_list>
        <measure>
          <title>Sensory Thresholds for Discomfort</title>
          <description>When participants felt pain at earliest pressure; range 0-65 mmHg</description>
          <population>1 participant in marinol and 1 participant in placebo did not have this information completed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="5.48"/>
                    <measurement group_id="O2" value="5" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="13.04"/>
                    <measurement group_id="O2" value="2" spread="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensory Thresholds for Pain</title>
        <description>When highest amount of pain was felt; range is 0-65 mmHg</description>
        <time_frame>Baseline and 1 month</time_frame>
        <population>1 participant in marinol and 1 participant in placebo did not have this information completed</population>
        <group_list>
          <group group_id="O1">
            <title>Marinol</title>
            <description>Marinol: 5mg BID, orally for 1 month</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 5mg BID, orally for 1 month</description>
          </group>
        </group_list>
        <measure>
          <title>Sensory Thresholds for Pain</title>
          <description>When highest amount of pain was felt; range is 0-65 mmHg</description>
          <population>1 participant in marinol and 1 participant in placebo did not have this information completed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="16.81"/>
                    <measurement group_id="O2" value="53" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="16.8"/>
                    <measurement group_id="O2" value="51" spread="15.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Marinol</title>
          <description>Marinol: 5mg BID, orally for 1 month</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: 5mg BID, orally for 1 month</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Viral Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ron Schey</name_or_title>
      <organization>Temple University</organization>
      <phone>215-707-9900</phone>
      <email>Ron.schey@tuhs.temple.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

